Onpattro (Patisiran Sodium,Lipid Complex) Patent Expiration, LOE Window & CMS Spending

Onpattro (Patisiran Sodium,Lipid Complex) by Alnylam Pharmaceuticals: FDA Orange Book core substance LOE 2035-08-27, 0 AB generics, $9.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlnylam Pharmaceuticals
FDA Application & PathwayN210922 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2035-08-27
Last Listed Patent or Exclusivity Date2035-08-27
Orange Book Patents (*PED Extensions)13 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$9.6M
2024 Medicare Part D Spend$7.0M
2024 Medicaid Spend$2.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alnylam Pharmaceuticals across sibling Meru public-data platforms.